News

CVS Health recently announced that long-serving director Larry M. Robbins resigned from its board in August 2026 and that Teresa Heitsenrether, Executive Vice President and Chief Data & Analytics Officer at JPMorgan Chase, will join as an independent director in November 2026. Alongside this governance shift, CVS Pharmacy launched its Home Team Heroes youth soccer initiative, underlining the company’s emphasis on community engagement and brand building at a time when analysts are focused on...

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

CVS Health has had an impressive run over the past six months as its shares have beaten the S&P 500 by 12.8%. The stock now trades at $93.94, marking a 23.3% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Medicare's improvement is real but not a turn in cost trend, while commercial costs keep running higher and the margin fix there has slipped again.

One of the pharmacy operator's segments is doing particularly well.

The healthcare giant is wrestling with costs in one part of its business, and the stock's recent dip has investors wondering if this is the moment to step in.

Mark Cuban says AI will never replace radiologists, and his reasoning has nothing to do with capability. The real disruption, he argues, targets a different layer of medicine entirely, one worth hundreds of billions in enterprise value at some of the biggest names in healthcare.

The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

Walmart beat revenue estimates and raised its full-year outlook, yet its stock still fell as investors zeroed in on one ugly number. The real reason behind that miss has nothing to do with shoppers tightening their belts.

CVS Health stock has delivered a 58.7% return over the past three years, yet its current valuation checks still lean toward the shares looking inexpensive on several fronts. Recent headlines around growth in healthcare services and legal disputes create a mixed backdrop for anyone trying to work out what that price implies. Over the last three years CVS Health has returned 58.7%, which puts recent swings into context and suggests investors have already re-rated the stock...

With stocks in bullish mode it’s a good time to run Barchart’s Bull Call Spread Screener.

CVS Health (CVS) is back in focus after a board reshuffle and fresh financial milestones. Recent earnings, guidance and management changes give investors new information to weigh around the stock’s current pricing. See our latest analysis for CVS Health. CVS Health’s recent board reshuffle and raised earnings guidance have come alongside mixed momentum, with the 1 month share price return down 11.69% but year to date share price return at 18.45%, and a 1 year total shareholder return of...

CVS Health (NYSE: CVS) announced that board member Larry M. Robbins has resigned from the Board of Directors. The company has appointed Teresa Heitsenrether, a senior executive from JPMorgan Chase with deep experience in data and analytics, to the CVS Health board. The board change highlights CVS Health's focus on technology, data and digital healthcare capabilities at the governance level. For investors who view data driven healthcare as a wider theme rather than solely a CVS Health story,...

Costco stock reclaimed a key technical level on Tuesday as the warehouse club climbed amid news of a partnership to offer Medicare Advantage plans to members. Costco Wholesale will offer co-branded plans in partnership with nonprofit health insurer Scan Group. Scan, based in Long Beach, Calif., has about 560,000 Medicare Advantage members in Southern California, Arizona, Nevada, New Mexico and Texas, according to the Wall Street Journal.

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

CVS delivers strong Q2 growth and raises 2026 targets, but Caremark pressures and medical costs are likely to shape its next move.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

JPMorgan’s data and analytics chief is joining CVS’ board this fall, while the CEO of activist hedge fund Glenview Capital Management is leaving after a two-year stint.

CVS Health enters the second half of 2026 with stronger earnings and Aetna gains, but medical costs and Caremark risks cloud the recovery.

CVS Health's Q2 EPS jumps more than 40% as Health Care Benefits profitability improves, prompting a major boost to its 2026 AOI outlook.

CVS Health is rebuilding momentum as Aetna drives stronger profits and higher 2026 guidance, but medical costs and PBM changes could test the recovery.

CVS Health advances its $20 billion technology push with AI tools, Health100 and automation aimed at simplifying care and improving engagement.

CVS Health (NYSE:CVS) reports that employers show higher trust in pharmacy benefit managers to manage drug costs and access to complex treatments, according to a new CVS Caremark survey. The company is rolling out new digital tools for its PBM clients to manage pharmacy benefits and monitor prescription spending. CVS is expanding coverage for biosimilars and GLP-1 therapies across its pharmacy network with a focus on affordability. Affordability driven changes across the CVS pharmacy network...

CVS Health’s second quarter was marked by better-than-expected revenue and profit, but investor sentiment was dampened by rising concerns over sustainability of these results. Management cited strong performance across all business segments, particularly from specialty pharmacy and Medicare Advantage, as key drivers. CEO David Joyner acknowledged, “the cumulative impact of these actions [in Aetna and Caremark] is starting to come through clearly in our results.” However, management also highligh

Management had named the plan exits, the Medicare margin target and the repricing date before the run began.

Management has raised its full-year earnings outlook twice, and the segment doing most of the lifting is still short of its own target margin.

UnitedHealth's lower medical costs are fueling an earnings recovery, but rising commercial costs and 2027 pricing decisions could test its durability.

Adjusted EPS surged 42.5% on margin recovery across all operating segments.